A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 2 54-2, 2003, Pages

  Bobofchak, Kevin M ^a   Mito, Toshiaki ^a   Texel, Sarah J ^a   Bellelli, Andrea ^b   Nemoto, Masaaki ^a   Traystman, Richard J ^a   Koehler, Raymond C ^a   Brinigar, William S ^c   Fronticelli, Clara ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNR   (Italy)

^c Temple University   (United States)

Author keywords

Artificial oxygen carriers; Blood substitutes; Exchange transfusion; Extravasation; Focal cerebral ischemia; Hemoglobin polymeric; Hemoglobin recombinant; Hemoglobin retention time; Hemoglobin synthetic; Transfusional fluids

Indexed keywords

CYSTEINE; HEME; NITRIC OXIDE; RECOMBINANT HEMOGLOBIN;

ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; CIRCULATION; CONTROLLED STUDY; ESCHERICHIA COLI; EXCHANGE BLOOD TRANSFUSION; HALF LIFE TIME; HUMAN; HYPERVOLEMIA; NONHUMAN; OXIDATION; OXYGEN AFFINITY; OXYGEN TRANSPORT; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN DENATURATION; PROTEIN STABILITY; PROTEIN SYNTHESIS;

ESCHERICHIA COLI;

EID: 0037623907     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00037.2003     Document Type: Article

References (53)

1. Adamson J, Bonaventura BJ, and Song S. Production, characterization, and clinical evaluation of hemolink, an oxidized raffinose cross-linked hemoglobin-based blood substitute. In: Red Cell Substitutes. Basic Principles and Clinical Applications. New York: Dekker, 1998.
2. Alayash AI. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat Biotechnol 17: 545-549, 1999.
3. Asano Y, Koehler RC, Ulatowski JA, Traystman RJ, and Bucci E. Effect of cross-linked hemoglobin transfusion on endothelial-dependent dilation in cat pial arterioles. Am J Physiol Heart Circ Physiol 275: H1313-H1321, 1998.
4. Balla G, Vercellotti GM, Muller-Eberhard U, Eaton J, and Jacob HS. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest 64: 648-655, 1991.
5. Baudin-Creuza V, Fablet C, Zal F, Green BN, Prome D, Marden MC, Pagnier J, and Wajcman H. Hemoglobin Porto Alegre forms a tetramer of tetramers superstructure. Protein Sci 11: 129-136, 2002.
6. Bleeker WK, van der PJ, Feitsma RI, Agterberg J, Rigter G, Vries-van Rossen A, Pauwels EK, and Bakker JC. In vivo distribution and elimination of hemoglobin modified by intramolecular cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate. J Lab Clin Med 113: 151-161, 1989.
7. Bonaventura J and Riggs A. Polymerization of hemoglobins of mouse and man: structural basis. Science 158: 800-802, 1967.
8. Bucci E, Razynska A, Kwansa H, Matheson-Urbaitis B, O'Hearne M, Ulatowski JA, and Koehler RC. Production and characteristics of an infusible oxygen-carrying fluid based on hemoglobin intramolecularly cross-linked with sebacic acid. J Lab Clin Med 128: 146-153, 1996.
9. Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, Pierce CH, and Greenburg AG. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med 28: 2283-2292, 2000.
10. Chang TM, D'Agnillo F, Yu WP, and Razack S. Two future generations of blood substitutes based on polyhemoglobin-SOD-catalase and nanoencapsulation. Adv Drug Delivery Res 40: 213-218, 2000.
11. Conover CD, Malatesta P, Lejeune L, Chang CL, and Shorr RG. The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG-Hb) in a conscious porcine model. J Investig Med 44: 238-246, 1996.
12. D'Agnillo F and Alayash AI. Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin. Adv Drug Delivery Res 40: 199-212, 2000.
13. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, and Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 16: 672-676, 1998.
14. Doyle MP, Apostol I, and Kerwin BA. Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. J Biol Chem 274: 2583-2591, 1999.
15. Faivre-Fiorina B, Caron A, Fassot C, Fries I, Menu P, Labrude P, and Vigneron C. Presence of hemoglobin inside aortic endothelial cells after cell-free hemoglobin administration in guinea pigs. Am J Physiol Heart Circ Physiol 276: H766-H770, 1999.
16. Fronticelli C, Arosio D, Bobofchak KM, and Vasquez GB. Molecular engineering of a polymer of tetrameric hemoglobins. Proteins 44: 212-222, 2001.
17. Fronticelli C, Bobofchak KM, Karavitis M, Sanna MT, and Brinigar WS. Introduction of a new regulatory mechanism into human hemoglobin. Biophys Chem 98: 115-126, 2002.
18. Fronticelli C and Bucci E. Conformational and functional characteristics of bovine hemoglobin. Methods Enzymol 231: 150-163, 1994.
19. Fronticelli C, O'Donnell JK, and Brinigar WS. Recombinant human hemoglobin: expression and refolding of beta-globin from Escherichia coli. J Protein Chem 10: 495-501, 1991.
20. Gould S, Sehgal L, Sehgal H, and Moss GS. Transfusion. Science 16: 5-17, 1995.
21. Habler OP and Messmer KF. Tissue perfusion and oxygenation with blood substitutes. Adv Drug Delivery Res 40: 171-184, 2000.
22. Hargrove MS, Singleton EW, Quillin ML, Ortiz LA, Phillips GN Jr, Olson JS, and Mathews AJ. His64(E7)-Tyr apomyoglobin as a reagent for measuring rates of hemin dissociation. J Biol Chem 269: 4207-4214, 1994.
23. Hayashi A, Suzuki T, and Shin M. An enzymatic reduction system for metmyoglobin and methemoglobin and its application to functional studies of oxygen carriers. Biochim Biophys Acta 310:309-316, 1973.
24. Hoffman SJ, Looker DL, Roehrich JM, Cozart PE, Durfee SL, Tedesco JL, and Stetler GL. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 87: 8521-8525, 1990.
25. Hughes GS Jr, Antal EJ, Locker PK, Francom SF, Adams WJ, and Jacobs EE Jr. Physiology and pharmacokineties of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 24: 756-764, 1996.
26. Hughes GS Jr, Francome SF, Antal EJ, Adams WJ, Locker PK, Yancey EP, and Jacobs EE Jr. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126: 444-451, 1995.
27. Hui HL, Kavanaugh JS, Doyle ML, Wierzba A, Rogers PH, Arnone A, Holt JM, Ackers GK, and Noble RW. Structural and functional properties of human hemoglobins reassembled after synthesis in Escherichia coli. Biochemistry 38: 1040-1049, 1999.
28. Ji X, Karavitis M, Razynska A, Kwansa H, Vasquez G, Fronticelli C, Bucci E, and Gilliland GL. Alpha-subunit oxidation in T-state crystals of a sebacyl cross-linked human hemoglobin with unusual autoxidation properties. Biophys Chem 70: 21-34, 1998.
29. Looker D, Abbott-Brown D, Cozart P, Durfee S, Hoffman S, Mathews AJ, Miller-Roehrich J, Shoemaker S, Trimble S, Fermi G, Komiyama NH, Nagai K, and Stetler GL. A human recombinant haemoglobin designed for use as a blood substitute. Nature 356: 258-260, 1992.
30. Looker D, Mathews AJ, Neway JO, and Stetler GL. Expression of recombinant human hemoglobin in Escherichia coli. Methods Enzymol 231: 364-374, 1994.
31. Matheson B, Kwansa HE, Bucci E, Rebel A, and Koehler RC. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol 93: 1479-1486, 2002.
32. Miele AE, Santanche S, Travaglini-Allocatelli C, Vallone B, Brunori M, and Bellelli A. Modulation of ligand binding in engineered human hemoglobin distal pocket. J Mol Biol 290: 515-524, 1999.
33. Moore EG and Gibson QH. Cooperativity in the dissociation of nitric oxide from hemoglobin. J Biol Chem 251: 2788-2794, 1976.
34. Nagai K, Perutz MF, and Poyart C. Oxygen binding properties of human mutant hemoglobins synthesized in Escherichia coli. Proc Natl Acad Sci USA 82: 7252-7255, 1985.
35. Olson JS and Phillips GN Jr. Kinetic pathways and barriers for ligand binding to myoglobin. J Biol Chem 271: 17593-17596, 1996.
36. Page TC, Light WR, and Hellums JD. Prediction of microcirculatory oxygen transport by erythrocyte/hemoglobin solution mixtures. Microvasc Res 56: 113-126, 1998.
37. Page TC, Light WR, McKay CB, and Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res 55: 54-64, 1998.
38. Piro MC, Militello V, Leone M, Gryczynski Z, Smith SV, Brinigar WS, Cupane A, Friedman FK, and Fronticelli C. Heme pocket disorder in myoglobin: reversal by acid-induced soft refolding. Biochemistry 40: 11841-11850, 2001.
39. Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, and Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med 24: 1993-2000, 1996.
40. Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, Magde D, Magde MD Jr, Vandegriff KD, and Winslow RM. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem 273: 12128-12134, 1998.
41. Sakai H, Tsai AG, Kerger H, Park SI, Takeoka S, Nishide H, Tsuchida E, and Intaglietta M. Subcutaneous microvascular responses to hemodilution with a red cell substitute consisting of polyethyleneglycol-modified vesicles encapsulating hemoglobin. J Biomed Mater Res 40: 66-78, 1998.
42. Schimenti JC and Duncan CH. Ruminant globin gene structures suggest an evolutionary role for Alu-type repeats. Nucleic Acids Res 12: 1641-1655, 1984.
43. Schroeder WA, Shelton JR, Shelton JB, Apell G, Huisman TH, Smith LL, and Carr WR. Amino acid sequences in the β-chains of adult bovine hemoglobins C-Rhodesia and D-Zambia. Arch Biochem Biophys 152: 222-232, 1972.
44. Shen TJ, Ho NT, Simplaceanu V, Zou M, Green BN, Tam MF, and Ho C. Production of unmodified human adult hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 90: 8108-8112, 1993.
45. Snyder SR, Welty EV, Walder RY, Williams LA, and Walder JA. HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. Proc Natl Acad Sci USA 84: 7280-7284, 1987.
46. Stowell CP, Levin J, Spiess BD, and Winslow RM. Progress in the development of RBC substitutes. Transfusion 41: 287-299, 2001.
47. Tondo CV. Increased erythrocyte glutathion reductase activity in a hemoglobin Porto Alegre (beta 9 Ser replaced by Cys) carrier. Biochem Biophys Res Commun 105: 1381-1388, 1982.
48. Ulatowski JA, Bucci E, Razynska A, Traystman RJ, and Koehler RC. Cerebral blood flow during hypoxic hypoxia with plasma-based hemoglobin at reduced hematocrit. Am J Physiol Heart Circ Physiol 274: H1933-H1942, 1998.
49. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, Bucci E, Traystman RJ, and Koehler RC. Regional blood flow alterations after bovine fumaryl beta beta-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition. Crit Care Med 24: 558-565, 1996
50. Vadapalli A, Goldman D, and Popel A. Calculation of oxygen transport by red blood cells and hemoglobin solutions in capillaries. Artif Cells Blood Substit Immobil Biotechnol 30: 157-188, 2002.
51. Vandegriff KD, Rohlfs RJ, Magde MD Jr, and Winslow RM. Hemoglobin-oxygen equilibrium curves measured during enzymatic oxygen consumption. Anal Biochem 256: 107-116, 1998.
52. Vasquez GB, Karavitis M, Ji X, Pechik I, Brinigar WS, Gilliland GL, and Fronticelli C. Cysteines beta93 and beta112 as probes of conformational and functional events at the human hemoglobin subunit interfaces. Biophys J 76: 88-97, 1999.
53. Zhang L, Levy A, and Rifkind JM. Autoxidation of hemoglobin enhanced by dissociation into dimers. J Biol Chem 266: 24698-24701, 1991.